✦ LIBER ✦

Design and Synthesis of Potent, Non-peptide Inhibitors of HCV NS3 Protease

✍ Scribed by Xiaojun Zhang; Aaron C. Schmitt; Wen Jiang; Zelda Wasserman; Carl P. Decicco

Book ID: 108477419
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 158 KB
Volume: 13
Category: Article
ISSN: 0960-894X
DOI: 10.1016/s0960-894x(03)00032-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Design and Synthesis of Potent, Non-pept

Design and Synthesis of Potent, Non-peptide Inhibitors of HCV NS3 Protease.

✍ Xiaojun Zhang; Aaron C. Schmitt; Wen Jiang; Zelda Wasserman; Carl P. Decicco 📂 Article 📅 2003 🏛 John Wiley and Sons ⚖ 193 KB 👁 2 views

## Abstract For Abstract see ChemInform Abstract in Full Text.

Highly Potent Non-peptidic Inhibitors of

Highly Potent Non-peptidic Inhibitors of the HCV NS3/NS4A Serine Protease.

✍ David Sperandio; et al. et al. 📂 Article 📅 2003 🏛 John Wiley and Sons ⚖ 77 KB 👁 2 views

Design and Synthesis of Bicyclic Pyrimid

Design and Synthesis of Bicyclic Pyrimidinone-Based HCV NS3 Protease Inhibitors.

✍ Peter W. Glunz; Brent D. Douty; Carl P. Decicco 📂 Article 📅 2003 🏛 John Wiley and Sons ⚖ 156 KB 👁 2 views

Synthesis of new acylsulfamoyl benzoxabo

Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease

✍ Xianfeng Li; Yong-Kang Zhang; Yang Liu; Suoming Zhang; Charles Z. Ding; Yasheen 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 668 KB

HCV NS3/4A serine protease is essential for the replication of the HCV virus and has been a clinically validated target. A series of HCV NS3/4A protease inhibitors containing a novel acylsulfamoyl benzoxaborole moiety at the P1' region was synthesized and evaluated. The resulting P1-P3 and P2-P4 mac

Design and synthesis of novel fluoro ami

Design and synthesis of novel fluoro amino acids: synthons for potent macrocyclic HCV NS3 protease inhibitors

✍ Latha G. Nair; Stephane Bogen; Frank Bennett; Kevin Chen; Bancha Vibulbhan; Yuhu 📂 Article 📅 2010 🏛 Elsevier Science 🌐 French ⚖ 952 KB

The Hepatitis C Virus (HCV) is a major health hazard and its infection is a leading cause of chronic liver disease world wide. In our efforts toward the discovery of a back up to our first clinical candidate, Boceprevir (SCH 503034), we approached the depeptidization of the molecule through macrocyc

The Design of Potent, Non-Peptidic Inhib

The Design of Potent, Non-Peptidic Inhibitors of Hepatitis C Protease

✍ David M. Andrews; et al. et al. 📂 Article 📅 2003 🏛 John Wiley and Sons ⚖ 69 KB 👁 1 views